An article previewing news about a pharmaceutical company's regulatory submission for an inhaled therapy for a chronic lung condition, inviting readers to learn more about the filing and clinical trial context.
Key Takeaways
- We are open to conversations with prospective partners and investors who share our vision
- Food and Drug Administration has accepted a supplemental new drug application for nebulized Tyvaso (treprostinil)
- Filing was based on pooled positive results from the phase 3 TETON-1 and TETON-2 studies